

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1430 Alexandra, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/053,611 01/24/2002		Komelia Polyak	001107.00224	6175	
22907 7	590 09/10/2003				
BANNER &	WITCOFF	EXAMINER			
1001 G STREE SUITE 1100		WILDER, CYNTHIA B			
WASHINGTO	N, DC 20001		ART UNIT	PAPER NUMBER	
			1637	12	
			DATE MAILED: 09/10/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 10/053,611

Applicant(s)

POLYAK et al.

Examiner

Wilder

Art Unit 1237



The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
	or Reply				_			
THE N	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.							
		nay be available under the provisions of communication.	of 37 CFR 1.136 (a). In r	o event, however, m	nay a reply be	timely filed after SIX (6) MONTHS from the		
If the p If NO p Failure Any re	period for reph period for reph to reply with ply received b	y specified above is less than thirty (30	tutory period will apply ar will, by statute, cause the	nd will expire SIX (6) e application to becor	MONTHS fro ne ABANDOI	om the mailing date of this communication. NED (35 U.S.C. § 133).		
Status								
1) 💢	Respons	ive to communication(s) fi	led on <i>Jun 30, 20</i>	003		·		
2a) 💢	This acti	on is <b>FINAL</b> .	2b)□ This acti	on is non-final				
3) 🗌	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.							
Disposit	tion of Cla	aims						
4) 💢	Claim(s)	1-11 and 29-53				is/are pending in the application.		
4	a) Of the	above, claim(s)				is/are withdrawn from consideration.		
5) 🗆	Claim(s)		· · · · · · · · · · · · · · · · · · ·			is/are allowed.		
6) 💢	Claim(s)	1-11 and 29-53				is/are rejected.		
7) 🗌	Claim(s)					is/are objected to.		
8) 🗆	Claims _			are	subject 1	to restriction and/or election requirement.		
Applica	tion Pape	rs						
9) 🗆	The spec	cification is objected to by	the Examiner.					
10)								
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	The prop	oosed drawing correction f	iled on	is:	a) 🗆 ap	pproved b) $\square$ disapproved by the Examiner		
	If appro	ved, corrected drawings are	required in reply to	o this Office ac	tion.			
12)	2) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120								
13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) All b) Some* c) None of:								
•	1. Certified copies of the priority documents have been received.							
:	2. Certified copies of the priority documents have been received in Application No							
		application from the Ir	nternational Burea	tu (PCT Rule 1	7.2(a)).	ceived in this National Stage		
,		ached detailed Office action		•				
<ul> <li>14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).</li> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> </ul>								
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachm				priority driddri	0.0.0	. 33 720 6110,01 7211		
			4) Interview Sur	nmary (PTO-	413) Paper No(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		5) Notice of Info	ormal Patent	Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)								

### FINAL ACTION

Page 2

Applicant's amendment filed in Paper No. 11 is acknowledged. Claims 1-11 and 29-53 1. pending. All of the amendments and arguments have been thoroughly reviewed and considered. Any rejection not reiterated in thits action have been withdrawn as being obviated by the amendment of the claims.

#### This action is made FINAL.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Previous Rejections

3. The objection to the specification has been withdrawn in view of Applicant's amendment to the specification. The rejection under 35 U.S.C. 112 first paragraph has been withdrawn in view of Applicant's arguments. The double patenting rejection for claims 1-11 and 29-32 is maintained below.

## **Double Patenting**

4. Once again Applicant's attention is drawn to the nonstatutory double patenting rejection. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ

Application/Control Number: 10/053,611

Art Unit: 1637

761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPO 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal

disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). **5**0. Claims 1-11 and 29-32 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-27 of U.S. Patent No.6,344,322 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of '322 patent only slightly differs from the claimed invention in scope. For example, in the '322 patent the method to aid in detecting the presence of tumor cells in a patient comprises steps of identifying 12 specific single basepair mutations in a mitochondrial genome of a cell sample of a patient whereas the claims of the instant invention are not limited to any specific basepair mutations of the mitochondrial genome of a cell sample. The claims of the instant invention encompasses any single basepair mutations including those cited in the claims of the '322 patent. Thus, the difference in scope do not represent a patentable distinction.

Application/Control Number: 10/053,611

Art Unit: 1637

Conclusion

Page 4

6 No claims are allowed. However, the claims are free of the prior art and would be allowed

upon submission of a timely filed terminal disclaimer. THIS ACTION IS MADE FINAL.

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this FINAL action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this FINAL action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will

expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a)

will be calculated from the mailing date of the advisory action. In no event, however, will the

statutory period for reply expire later than SIX MONTHS from the mailing date of this FINAL

action.

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Examiner Cynthia Wilder whose telephone number is (703) 305-1680. The

examiner can normally be reached on Monday through Thursday from 9:30 am to 6:30 pm and on

Friday from 9:30 am to 1:30 pm.

Application/Control Number: 10/053,611

Art Unit: 1637

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached at (703) 308-1119. The official fax phone number for the Group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Group's receptionist at (703) 308-0196.

cbw September 8, 2003

Cynthia B. Wilder, Ph.D. Patent Examiner Art Unit 1637

**PRIMARY EXAMINER** 

Kentle. Hoht

Page 5

9/8/03